Claim Missing Document
Check
Articles

Found 2 Documents
Search

SINTESIS PEPTIDA P251-9 BERGUGUS PELINDUNG DENGAN METODE SINTESIS PEPTIDA FASA PADAT FMOC/TBU MENGGUNAKAN ADITIF OKSIMA Hardianto, Ari; Subroto, Toto; Supratman, Unang
Jurnal Sains dan Terapan Kimia Vol 5, No 2 (2011)
Publisher : Jurnal Sains dan Terapan Kimia

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Peptida P25 merupakan epitop yang dapat dengan mudah mengaktivasisel T penolong. Sel T penolong teraktivasi berperan dalam aktivasi sel Buntuk membentuk antibodi. Peptida bahkan protein dapat dibuat denganmetode sintesis peptida fasa padat Fmoc/tBu menggunakan aditif HOBt.Namun sayangnya HOBt memiliki karakter yang mudah meledak. Padapenelitian ini telah berhasil disintesis bagian epitop P25 (peptida P251-9bergugus pelindung) yang memiliki tingkat kemurnian tinggi dan perolehan36,4% dengan metode sintesis peptida fasa padat Fmoc/tBu menggunakanaditif oksima pengganti HOBt.Kata kunci: Epitop, P251-9, sintesis peptida fasa padat Fmoc/tBu, oksima.
Sintesis Tiga Peptida Bergugus Pelindung sebagai Prekursor Komponen Vaksin Influenza Universal Subroto, Toto; Hardianto, Ari; Kahari, Abdul Alim; Pradnjaparamita, Tika
Jurnal Natur Indonesia Vol 15, No 2 (2013)
Publisher : Lembaga Penelitian dan Pengabdian kepada Masyarakat Universitas Riau

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (533.702 KB) | DOI: 10.31258/jnat.15.2.84-91

Abstract

Current highly effective conventional vaccine to halt the spread of bird flu has not been invented yet because of susceptiblemutation of influenza virus. In spite of undergoing mutation which causes the amino acid sequence change, influenzaviruses maintain conservation at ectodomain of M2 protein, especially M2e(2-16) (SLLTEVETPIRNEW). The use ofconserved epitope M2e(2-16) in epitope-based vaccine potentially produces universal influenza vaccine. In designingepitope-based vaccine, the M2e(2-16) needs to be coupled with T helper epitope, P25, which is subsequently mentioned asM2e(2-16)-K-P25 (SLLTEVETPIRNEWGKKKL IPNASLIENCTKAEL). The M2e(2-16)-K-P25 was synthesized usingconvergent solid phase peptide synthesis strategy because of the size of the sequence. In this strategy, four peptideprecursors of M2e(2-16)-K-P25; SLLTEVETP (F1), IRNEWGK (F2), KLIPNASLI (F3), and ENCTKAEL (F4); were synthesizedin advance. After the precursors ready, coupling reaction was performed to obtain M2e(2-16)-K-P25. In the previousresearch, F3 has been obtained in high purity through Fmoc/tBu solid phase peptide synthesis method. In this conductedresearch, the three remaining precursors; F1, F2, and F4; were synthesized by the same method. Each peptide was analysedby thin layer chromatography, HPLC, and mass spectroscopy methods. F1, F2 and F4 were successfully synthesized andeach of them was detected at 1490.0, 1874.8 and 1881.9 amu, respectively. However, F1 was not possible to purify becauseof its insolubility in various solvents.